Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

Tremendous rebuttal by georgejj to an argument tha

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 311)
Posted On: 10/20/2017 10:34:12 PM
Posted By: petemantx
Tremendous rebuttal by georgejj to an argument that Prurisol (and IL-20) does not work against arthritis and the proof was that a clinical trial terminated that was a biologic IL-20 and it was testing against arthritis.

George came back with why the trial was terminated, because another was started where the treatment was based on the patients weight, and therefore was much more effective and safer. Well, the replacement trial showed IL-20 was a tremendous treatment against arthritis. He also showed that Prurisol is much safer and more effective than the biologic used in the replacement trial due to its chemical makeup.

From georgejji:

That trial was not a failure. The trial was terminated NCT01636817 because another trial had started with the subcutaneous dose titrated to the body weight of each subject in the trial. Titration of the dose to each subjects body weight is a much safer and effective method of treatment.

https://clinicaltrials.gov/show/NCT01282255

The results of the new trial with the dose titrated to each trial subject's body weight is that the NNC0109-0012, a selective anti-IL-20 recombinant human monoclonal antibody (mAb) both safe and very effective.

Quote:
In this phase IIa trial, treatment with NNC0109-0012 (anti-IL-20 mAb) was effective in patients with seropositive RA as early as week 1, with further improvements to week 12. No safety or tolerability concerns were identified with weekly NNC0109-0012 administration.


http://onlinelibrary.wiley.com/doi/10.1002/art.39083/full

Prurisol is not a monoclonal antibody and is taken oarally. Prurisol is much safer and more effective.


(4)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us